Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
Holding MNKD?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.03Last Year’s EPS
$0Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -14.75%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive overall sentiment with strong revenue growth and successful collaborations driving optimism. However, challenges like Afrezza headwinds and market difficulties in NTM lung disease were noted.Company Guidance
In the MannKind Corporation Q3 2024 earnings call, the company provided guidance reflecting strong financial performance and strategic advancements. The EBU net revenue reached $20 million, marking a 10% increase from the previous year, while Afrezza grew by 16% year-over-year despite facing headwinds. The company reported $268 million in cash and a $15 million non-GAAP operating income for the quarter. MannKind's collaboration with United Therapeutics generated significant revenue, contributing to a 37% increase in total Q3 revenues to $70 million, and a 49% increase year-to-date to $209 million. The company's pipeline developments, including the clofazimine inhalation studies and nintedanib DPI, promise future growth. Additionally, Afrezza's new prescriptions rose by 8% year-over-year, with a focus on profitable growth, and significant clinical progress was made in diabetes management, with substantial improvements in A1c levels and patient outcomes. MannKind aims to continue its momentum, with strategic focus areas set to further capitalize on clinical and commercial opportunities.Strong Revenue Growth
Third quarter revenues were $70 million, representing a 37% increase compared to the same quarter last year. Year-to-date revenues were $209 million, a 49% increase over the prior year period.
Tyvaso DPI Collaboration Success
Tyvaso DPI royalties contributed $27 million in third-quarter revenue, marking a 34% increase over the same quarter last year.
Positive Afrezza Performance
Afrezza net revenue for the third quarter was $15 million, a 12% increase due to higher demand and improved gross to nets.
Strong Financial Position
MannKind has $268 million in cash and achieved a non-GAAP operating income of $15 million for the quarter.
Progress in Clinical Development
Significant progress reported in the TENA Phase I and clofazimine inhalation studies, with ongoing opportunities in the U.S. and Asia.
---
MNKD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MNKD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $7.39 | $7.34 | -0.68% |
| Aug 07, 2024 | $5.27 | $5.01 | -4.93% |
| May 08, 2024 | $4.40 | $4.31 | -2.05% |
| Feb 27, 2024 | $3.78 | $3.92 | +3.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mannkind Corp. (MNKD) report earnings?
Mannkind Corp. (MNKD) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Mannkind Corp. (MNKD) earnings time?
Mannkind Corp. (MNKD) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MNKD EPS forecast?
MNKD EPS forecast for the fiscal quarter 2024 (Q4) is $0.03.
---